Orphan drugs: Treatments for rare diseases are gaining ground around the world

Rare diseases have always been one of the greatest challenges facing modern medicine.

Although each condition affects a relatively small number of people, their collective impact is significant. According to the European Medicines Agency (EMA), approximately 36 million people live with rare diseases in the European Union alone.

For many years, the development of treatments for these conditions faced significant obstacles. The small number of patients, high research costs, and commercial uncertainties meant that many diseases received little attention from the pharmaceutical industry.

However, that situation has begun to change.

Advances in genetics, biotechnology, and personalized medicine—combined with regulatory incentives created by agencies such as the FDA and the EMA—have driven the development of so-called orphan drugs, therapies targeting rare diseases that are gaining increasing prominence in clinical research and the global pharmaceutical market.

What are orphan drugs?

The term is used to refer to drugs intended for the prevention, diagnosis, or treatment of rare diseases. Because these conditions affect a small number of patients, many of them have historically received less funding compared to more common diseases.

A disease is considered rare when it affects a small portion of the population. Although each individual disease affects only a few patients, there are thousands of rare diseases identified worldwide.

According to the National Organization for Rare Disorders (NORD), it is estimated that more than 300 million people worldwide live with rare diseases, highlighting the importance of this issue for health care systems.

Why is the orphan drug market growing?

The growth of the orphan drug market is directly linked to the scientific advances seen in recent years.

Genetic sequencing technologies, artificial intelligence, molecular biology, and precision medicine are enabling researchers to identify specific causes of various rare diseases and develop more targeted treatments.

In addition, regulatory agencies such as the FDA and EMA offer incentives that help reduce risks and stimulate investment in areas that were previously considered economically unfeasible.

The result is a steady increase in the number of therapies for rare diseases, expanding treatment options for patients around the world.

The Impact of Personalized Medicine

Most orphan drugs are linked to the growth of personalized medicine.

Instead of developing broad treatments for large populations, researchers are able to create therapies targeted at specific genetic characteristics or smaller groups of patients.

This approach has driven progress in areas such as:

• Rare genetic diseases;
• Metabolic diseases;
• Neurological diseases;
• Immunodeficiencies;
• Certain types of cancer.

Therefore, these therapies represent the first available treatment option for patients who previously had limited treatment options.

A growing market

Advances in orphan drugs are also transforming the global pharmaceutical market.

According to analyses by the IQVIA Institute, therapies for rare diseases have been accounting for a growing share of the pharmaceutical industry’s research and development investments.

Furthermore, this growth is driven both by scientific advances and by the search for solutions to unmet medical needs.

As new technologies enter the market, the number of treatments available for rare diseases is expected to continue to increase in the coming years.

The challenges continue

Despite the progress made, there are still significant obstacles to the development and availability of these treatments.

Among the main challenges are:

• High research and development costs;
• Delayed diagnosis of rare diseases;
• Difficulty recruiting patients for clinical trials;
• Regulatory complexity;
• Access to treatment in different countries.

However, because many rare diseases affect small populations, generating robust clinical evidence remains one of the most challenging steps in the development process.

When Innovation and Necessity Go Hand in Hand

The growth of orphan drugs demonstrates how scientific innovation can open up new possibilities for patients who, for decades, have had few treatment options available to them.

Driven by advances in genetics, biotechnology, and personalized medicine, these treatments are expanding treatment options for thousands of rare diseases around the world.

More than just a trend in the pharmaceutical industry, orphan drugs represent a significant shift in the way science seeks to address medical needs that were once considered unfeasible, underscoring the potential of innovation to transform lives.